Transcode Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
RNAZ Nasdaq 8731 https://www.transcodetherapeutics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Transcode Therapeutics Inc

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate - Sep 17th, 2024 11:00 am
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer - Sep 10th, 2024 11:00 am
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate - Sep 5th, 2024 11:00 am
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation - Aug 15th, 2024 11:00 am
TransCode Therapeutics, Inc. Announces Closing of Public Offering - Jul 24th, 2024 8:05 pm
TransCode Therapeutics, Inc. Announces Pricing of Public Offering - Jul 23rd, 2024 2:30 am
TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock - Jul 22nd, 2024 8:07 pm
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements - Jun 10th, 2024 11:00 am
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138 - May 29th, 2024 1:15 pm
TransCode Therapeutics Open Letter to Shareholders - May 13th, 2024 12:30 pm
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors - Apr 15th, 2024 1:00 pm
TransCode Therapeutics Reports 2023 Results; Provides Business Update - Apr 3rd, 2024 1:10 pm
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer - Mar 28th, 2024 12:30 pm
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment - Mar 11th, 2024 1:00 pm
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress - Mar 6th, 2024 9:15 pm
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic - Feb 20th, 2024 1:00 pm
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market - Jan 31st, 2024 9:05 pm
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer - Jan 29th, 2024 1:30 pm
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering - Jan 22nd, 2024 9:45 pm
TransCode (RNAZ) Down 50% on Issue of New Common Stock - Jan 19th, 2024 6:09 pm